50 MO P C MO P C , L C MV 40 re la tive V L 4 e xp re ssi o n › original › nature-assets ›...
Transcript of 50 MO P C MO P C , L C MV 40 re la tive V L 4 e xp re ssi o n › original › nature-assets ›...
![Page 1: 50 MO P C MO P C , L C MV 40 re la tive V L 4 e xp re ssi o n › original › nature-assets › ...MOPC tumor bearing C57BL/6J mice were treated with 2x104 PFU LCMV peritumorally](https://reader033.fdocuments.in/reader033/viewer/2022060207/5f03fa9c7e708231d40bb751/html5/thumbnails/1.jpg)
Supplementary Figure 1: LCMV replicates in MOPC without affecting cell proliferation a: Quantification of Immunofluorescence of MOPC cells untreated or infected with LCMV (MOI 1) 72 hours after infection (n = 3/group) (related to Fig. 1c). ns, non-significant. b: Non-impaired clonogenic survival of MOPC cells after in vitro LCMV WE infection. Representative photograph of long-term colony formation following incubation of MOPC with LCMV WE of indicated MOI.
Supplementary Figure 1
d1 d2 d30
10
20
30
40
50
% D
AP
I+ A
rea relative VL4 expression
MOPC, LCMV
MOPC
MOI 1 MOI 0.5 MOI 0.25
MOI 0.125 MOI 0.0625 untreated
b a
ns
ns
ns
![Page 2: 50 MO P C MO P C , L C MV 40 re la tive V L 4 e xp re ssi o n › original › nature-assets › ...MOPC tumor bearing C57BL/6J mice were treated with 2x104 PFU LCMV peritumorally](https://reader033.fdocuments.in/reader033/viewer/2022060207/5f03fa9c7e708231d40bb751/html5/thumbnails/2.jpg)
Supplementary Figure 2: B-Myb expression, and not IFN-I unresponsiveness, is one factor promoting arenavirus replication a: mRNA expression levels of Ifnar1 and Ifnar2 for the cancer types renal cell cancer (RCC; n=534), hepatocellular cancer (HCC; n=373), colorectal cancer (CRC; n=382), head and neck squamous cell cancer (HNSCC; n=522) and skin cutaneous melanomas (SKCM; n=471). Downloaded from the TCGA database by use of cBioPortal (www.cbioportal.org). Data are shown as mean and minimum-maximum whiskers. b: qRT-PCR of human Ifnar1 and Ifnar2 mRNA expression in Sw480, HeLa, HepG2, FADU cells and controls (murine mRNA, n=5/group). c: Number of viral plaques in Sw480 cell layer (n=6/group, left panel) and HeLa cell layer (n=5/group, right panel), which were
treated with different concentrations of human IFN4, murine IFN4 or murine IFN2 and infected with VSV (MOI 0.01) 24 hours earlier. d: qRT-PCR of murine Ifnar1 mRNA in MOPC cells, MC38 cells, B16F10 cells, LoxP-Tag tumors, MT/ret cells and control (human mRNA, n=5/group). e&f: Immunofluorescence of phospho-B-Myb (e, n=3/group) and qRT-PCR of B-Myb (=Mybl2) mRNA (f, n = 9-10/group) in MOPC, MC38 and LoxP-Tag tumors compared to the correlating healthy tissue (oropharyngeal epithelia, colon and liver). Scale bar, 200µm. g: qRT-PCR of viral host factors in MOPC tumors (n=5) and pharynx tissue (n=5). h: Infectious LCMV particles in supernatant of MCF7 cells, which were treated with control siRNA or two separate B-Myb siRNAs and then 24 hours later infected with LCMV (MOI 1) analyzed 24 hours after infection (n = 6/group). Data are shown as mean ± SEM and analyzed by unpaired Student`s t-test. ns, non significant; *p < 0.05; **p < 0.01; ***p < 0.001.
Supplementary Figure 2
0 2000 4000 6000 800010000
SKCM
HNSCC
CRC
HCC
RCC
IFNAR1 (relative expression)
0 1000 2000 3000
SKCM
HNSCC
CRC
HCC
RCC
IFNAR2 (relative expression)
a b
0.01 0.1 1 10
control
FADU
HepG2
HeLa
SW480
IFNAR1(relative expression)
0.01 0.1 1 10
IFNAR2(relative expression)
10 100 1000100000
hIFN-
mIFN-
mIFN-
IFN-I (U/ml)
10 100 100010000
0
20
40
60
0
IFN-I (U/ml)
VS
V (
PF
U/w
ell)
Sw480 c
d
0.1 1 10 100 1000
Control
MT/ret
LoxP-TAg
B16F10
MC38
MOPC
Ifnar1(relative expression)
WT, oropharynx
MOPC
WT, colon
MC38
WT, liver
LoxP-Tag
Norm
al tissue
T
um
or
e DAPI p-bmyb f
0.01 0.1 1 10 100
MOPC tumor
WT, oropharynx
MC38 tumor
WT, colon
LoxP-TAg, liver tumor
WT, liver
M y bl2 m RNA (F o ld c hange)
**
***
*
32 641 2 4 8 16
mRNA (relative expression, log scale)
TipinMOPC tumor
Pharynx*
**
**
***
ns
*
*
*
****
**
*Arhgap23
Atp6ap2
Atp6v0b
Pkmyt1
Arcn1
Copb1
Copa
Mat2a
Eif3g
Eif3a
Signal transduction
Uncoating
Translation regulation
Vesicular transport
GPCR signaling
g
3
4
5
6
Control siRNAB-Myb siRNA 1B-Myb siRNA 2
* *
<3
LC
MV
(log
10P
FU
/ml)
h
![Page 3: 50 MO P C MO P C , L C MV 40 re la tive V L 4 e xp re ssi o n › original › nature-assets › ...MOPC tumor bearing C57BL/6J mice were treated with 2x104 PFU LCMV peritumorally](https://reader033.fdocuments.in/reader033/viewer/2022060207/5f03fa9c7e708231d40bb751/html5/thumbnails/3.jpg)
Supplementary Figure 3: Intravenous infection leads to viral replication in metastasis a: Immunohistochemistry for LCMV-NP in flank and shoulder tumor (day 15) from C57BL/6 mice receiving simultaneously subcutaneously 5 x 10
5 MOPC cells in the flank and shoulder (day -3),
treated with or without 2x104 PFU LCMV given into the flank or intravenously on day 0 (n=4-5/group).
Scale bar, 200µm. b: Serum alanin-aminotransferase (ALT) levels of C57BL/6 (n=3) and adenovirally induced tumor bearing LoxP-TAg mice (11 month old) which were left untreated (n=4) or which were additionally treated with 2 x 10
6 PFU of LCMV-WE (n=5) measured 20 days after infection. Values
above line indicate pathological liver disease.
LCMV ( into Flank LCMV (i.v.) untreated
Should
er
tum
or
Fla
nk tu
mor
LC
MV
-NP
Supplementary Figure 3
a
b
0
500
1000
1500
LoxP-TAgcontrol
LoxP-TAgLCMV
C57BL/6LCMV
4/4 1/5 0/3
*
ALT
(U
/ml)
![Page 4: 50 MO P C MO P C , L C MV 40 re la tive V L 4 e xp re ssi o n › original › nature-assets › ...MOPC tumor bearing C57BL/6J mice were treated with 2x104 PFU LCMV peritumorally](https://reader033.fdocuments.in/reader033/viewer/2022060207/5f03fa9c7e708231d40bb751/html5/thumbnails/4.jpg)
Supplementary Figure 4: Immune cell infiltrates are required for tumor regression Tumor diameter of MOPC-tumor bearing WT and Map3k14
aly/aly mice (day -3) treated with (n=8 WT;
n=6 Map3k14aly/aly
) or without (n=7 WT; n=6 Map3k14aly/aly
) 2x104 PFU LCMV peritumorally on day 0.
Data are shown as mean ± SEM and analyzed by unpaired Student`s t-test. ns, non significant; ***p < 0.001.
Supplementary Figure 4
![Page 5: 50 MO P C MO P C , L C MV 40 re la tive V L 4 e xp re ssi o n › original › nature-assets › ...MOPC tumor bearing C57BL/6J mice were treated with 2x104 PFU LCMV peritumorally](https://reader033.fdocuments.in/reader033/viewer/2022060207/5f03fa9c7e708231d40bb751/html5/thumbnails/5.jpg)
Supplementary Figure 5: Tumor infiltrating Ly6C+ cells are indispensable for antitumoral LCMV therapy MOPC tumor bearing C57BL/6J mice were treated with 2x10
4 PFU LCMV peritumorally on day 0.
Depletion was performed by i.p. injection of either (a) αLy6C+G (clone RB6-8C5) 200µg or (b and c) αly6G (clone 1A8) 500µg starting on d-2 and repeated on d2 and d7. a&b: Representative dot blots of peripheral vein blood collected on d4 and stained for monocyte and granulocyte cell markers after preselection of CD11b positive cells. c: Tumor diameter in C57BL/6 mice injected with or without αLy6G (1A8) antibody (n=3-4/group). Data are shown as mean ± SEM and analyzed by unpaired Student`s t-test. ns, non-significant.
SSC
CD115
WT
, un
dep
lete
d
WT
, αly
6G
(c
lon
e 1
A8
)
MC
nG
nG
MC
nG MC nG MC
Ly6G
cou
nt
Ly6C
SSC
CD115
WT
, un
dep
lete
d
WT
, αL
y6
C+
G
(clo
ne
RB
6-8
C5
)
MC
nG
nG
MC
nG MC nG MC
Ly6G
cou
nt
Ly6C
0 5 1 0 1 5
0 .2
0 .4
0 .6
0 .8
1 .0
1 .2
< 0 .1
W T , L y 6 G
W Tn s
T im e ( d )
Tu
mo
r d
ia
me
te
r (c
m)
0 5 10 15
WT, Ly6G,LCMV
WT, LCMV ns
Time (d)
c
a
b
Supplementary Figure 5
![Page 6: 50 MO P C MO P C , L C MV 40 re la tive V L 4 e xp re ssi o n › original › nature-assets › ...MOPC tumor bearing C57BL/6J mice were treated with 2x104 PFU LCMV peritumorally](https://reader033.fdocuments.in/reader033/viewer/2022060207/5f03fa9c7e708231d40bb751/html5/thumbnails/6.jpg)
Supplementary Figure 6: Impact of adaptive immune system and NK cells on LCMV-induced anti-tumoral immunity. a: Tumor diameter of MOPC-tumor bearing WT and Tcrab
–/– mice (day -3) treated with or without
2x104 PFU LCMV peritumorally on day 0 (n=5/group). b: Tumor diameter of MOPC-tumor bearing WT
and Jh–/–
mice (day -3) treated with or without 2x104 PFU LCMV peritumorally on day 0 (n=5/group).
c&d: Tumor diameter (c) and representative dot blot from peripherial vein blood collected at day 2 and stained for NK cell markers (d) of WT mice which were NK depleted by i.p. injection of 400µl NK1.1 antibody on day -3 and day -1 (n = 4/group). Data are shown as mean ± SEM and analyzed by unpaired Student`s t-test. ns, non-significant.
Supplementary Figure 6
a
0 5 10 15 20 25 30
WT, LCMVTcrb–/–, LCMV
Time (d)
0 5 10 15 20 25 300.0
0.2
0.4
0.6
0.8
1.0
1.2
<0.1
WTTcrb–/–
Time (d)
Tu
mor
dia
mete
r (c
m)
ns ns
b
0 5 10 15 20 25 30
Jh–/–, LCMVWT, LCMV
Time (d)
0 5 10 15 20 25 300.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
<0.1
WTJh–/–
Time (d)
Tu
mor
dia
mete
r (c
m)
ns ns
c
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
<0.1
WT, NK1.1
WT
Time (d)
Tum
or
dia
me
ter
(cm
)
0 5 1 0 1 5 2 0
W T, NK 1 .1 , L C M V
W T , LC M V
Time (d)
ns ns
NK
1.1
CD3
d
![Page 7: 50 MO P C MO P C , L C MV 40 re la tive V L 4 e xp re ssi o n › original › nature-assets › ...MOPC tumor bearing C57BL/6J mice were treated with 2x104 PFU LCMV peritumorally](https://reader033.fdocuments.in/reader033/viewer/2022060207/5f03fa9c7e708231d40bb751/html5/thumbnails/7.jpg)
Supplementary Figure 7: Monocyte recruitment in human cancers correlates with IFN-I induction a: Heatmap of correlation analyses of 12 immunogenes mRNAs of primary samples from 34 oropharyngeal cancer patients. b: Linear regression between IRF7 and the human monocyte markers CD14 and CD16. c: Gene-set enrichment analysis (GSEA) of human IFN-I induced genes by usage of the Browne interferon-related gene-set. IFN-I-induced expression profile and genes ranked by extent of differential expression in TCGA melanoma, hepatocellular carcinoma, renal cancer, head and neck cancer and colorectal cancer dataset. NES, normalized enrichment score; FDR, false discovery rate.
Supplementary Figure 7
0 2 4 6 80
5
10
15
CD16 normalized expression
IRF
7 n
orm
alized e
xpre
ssio
n R square 0.5668P value < 0.0001
0 2 4 6 80
5
10
15
CD14 normalized expression
IRF
7 n
orm
alized e
xpre
ssio
n R square 0.4812
P value < 0.0001
c
a b
![Page 8: 50 MO P C MO P C , L C MV 40 re la tive V L 4 e xp re ssi o n › original › nature-assets › ...MOPC tumor bearing C57BL/6J mice were treated with 2x104 PFU LCMV peritumorally](https://reader033.fdocuments.in/reader033/viewer/2022060207/5f03fa9c7e708231d40bb751/html5/thumbnails/8.jpg)
Supplementary Figure 8: Virus-specific memory CD8
+ T cells prevent LCMV-induced tumor
regression a: Tumor diameter of MOPC-tumor bearing WT or memory Jh
–/– mice (pretreated with 200 PFU LCMV
i.v. 100 days before tumor inoculation) treated with LCMV 2x104 PFU intravenously on day 0 (n =
5/group). b: Tumor diameter and survival from MOPC-tumor transplanted WT and Rag1–/–
mice (day -10) treated with or without 2x10
4 PFU LCMV intratumorally on day 0 (n = 5/group) c: Tumor diameter
and survival from MOPC-tumor transplanted Rag1–/–
mice (day -10) treated with anti-IFNAR1 antibody or isotype control (n = 5/group). Data are shown as mean ± SEM and analyzed by unpaired Student`s t-test. Survival is shown in Kaplan-Meier method and analyzed by log-rank test. ns, non-significant; *p < 0.05; **p < 0.01; ***p < 0.001.
Supplementary Figure 8
a
- 1 0 - 5 0 5 1 0 1 5 2 0
0 . 3
0 . 6
0 . 9
1 . 2
1 . 5
< 0 . 1
W T , L C M V
m e m o r y J h – / – , L C M V
T i m e ( d )
Tu
mo
r d
ia
me
te
r (
cm
)
**
b
0 10 20 30 40 50 60 700.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
Rag1–/–WT
Time (d)
Tum
or
dia
me
ter
(cm
)
0 20 40 60 800
20
40
60
80
100
Rag1–/–
, LCMV
WT, LCMV
Time (d)
Surv
ival (%
)
0 10 20 30 40 50 60 70
WT, LCMV
Rag1–/–, LCMV
Time (d)
** ** ns
c
0 5 10 15 20 25 30 350.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
Rag1–/–, aIFNAR, LCMV
Rag1–/–, Isotype control, LCMV
Time (d)
Tum
or
dia
mete
r (c
m)
0 20 40 60 800
20
40
60
80
100
Rag1–/–, Isotype control, LCMV
Rag1–/–, anti-IFNAR, LCMV
Time (d)
Surv
ival (
%)
*** **
![Page 9: 50 MO P C MO P C , L C MV 40 re la tive V L 4 e xp re ssi o n › original › nature-assets › ...MOPC tumor bearing C57BL/6J mice were treated with 2x104 PFU LCMV peritumorally](https://reader033.fdocuments.in/reader033/viewer/2022060207/5f03fa9c7e708231d40bb751/html5/thumbnails/9.jpg)
Supplementary Figure 9: Anti-tumoral effect of LCMV is independent of host IFNAR expression. Tumor diameter of Ifnar
–/– and C57BL/6 control mice injected with 5x10
5 MOPC cells (day -3)
subcutaneously and either left untreated (left) or treated with 2x104 PFU LCMV peritumorally (right,
day 0) (n = 6-7/group). Measurements were performed on the indicated days. ns, non-significant.
Supplementary Figure 9
Control LCMV
0 5 10 15 20 25
0.2
0.4
0.6
0.8
1.0
1.2
<0.1
Time (d)
Tum
or
dia
mete
r (c
m)
0 5 10 15 20 25
Time (d)
C57BL/6J
Ifnar–/–
C57BL/6J, LCMV
Ifnar–/–
, LCMV
ns
ns
![Page 10: 50 MO P C MO P C , L C MV 40 re la tive V L 4 e xp re ssi o n › original › nature-assets › ...MOPC tumor bearing C57BL/6J mice were treated with 2x104 PFU LCMV peritumorally](https://reader033.fdocuments.in/reader033/viewer/2022060207/5f03fa9c7e708231d40bb751/html5/thumbnails/10.jpg)
Supplementary Figure 10: Reduced vascularisation correlates with arenavirus mediated tumor regression a: qRT-PCR from tumors of MOPC-tumor bearing WT mice (day -3) treated with or without 2x10
4 PFU
LCMV peritumorally (day 0), analyzed on day 6 (n= 3/group). b&c: Immunofluorescence (b, n= 3/group, CD31, red; DAPI, blue) and quantification of microvessel density (MVD) and vessel–vessel distances (c, n = 3/group) from MOPC-tumor bearing C57BL/6 mice (day -3) which were treated with or without 2x10
4 PFU LCMV peritumorally (day 0) measured on day 6. d: Immunohistochemistry (day
6) and quantification (day 9) of hypoxic areas from tumors of MOPC-tumor bearing C57BL/6 mice (day -3) treated with or without 2x10
4 PFU LCMV peritumorally on day 0 (n= 3 mice/group). e:
Immunofluorescence of tumors from MOPC-tumor bearing C57BL/6 (day -3) treated with or without 2x10
4 PFU LCMV peritumorally on day 0 (n= 3/group, Ki-67 or cleaved caspase 3, red; DAPI, blue).
Data are shown as mean ± SEM and analyzed by unpaired Student`s t-test. ns, non-significant; *p < 0.05 ; **p < 0.01; ***p < 0.001; Scale bar = 200µm.
a Tumor, LCMV Tumor
Log2
-10 0 10
Supplementary Figure 10
DA
PI C
D31
Tumor
Tumor, LCMV
b Tumor Tumor, LCMV
c
Control LCMV0
1 0 0
2 0 0
3 0 0
Ve
ss
el-
ve
ss
el
dis
tan
ce
(µ
m)
***
Control LCMV0
2 0 0
4 0 0
6 0 0
8 0 0
MV
D (
mm
³)
* *
d
Pim
onid
azo
l
Tumor Tumor, LCMV
Control LCMV0
20
40
60
Hyp
oxi
c a
rea (
%)
**
Tumor Tumor, LCMV
DA
PI K
i 6
7
DA
PI
Cle
ave
d C
asp
ase 3
e
![Page 11: 50 MO P C MO P C , L C MV 40 re la tive V L 4 e xp re ssi o n › original › nature-assets › ...MOPC tumor bearing C57BL/6J mice were treated with 2x104 PFU LCMV peritumorally](https://reader033.fdocuments.in/reader033/viewer/2022060207/5f03fa9c7e708231d40bb751/html5/thumbnails/11.jpg)
Supplementary Table 1: List of antibodies used for immunofluorescence. All antibodies listed were used in 1:100 dilutions to their original concentration for flow-cytometry and/or for immunohistochemistry.
Antibody Manufacturer Catalogue number
Anti-B MyB (phospho T487) Origene TA301225
Anti-CD90.2 eBiosciences 11-0903
Anti-CD4 BD Pharmingen 17-0042
Anti-CD8 eBiosciences 553035
Anti-CD45R (B220) BD Pharmingen 17-0452
Anti-Ly6C eBiosciences 17-5932
Anti-Ly6G eBiosciences 11-5931
Anti-CD115 eBiosciences 12-1152
Anti-CD11b eBiosciences 47-0112
Anti-CD11c eBiosciences 11-0114
Anti-mPDCA Miltenyi 130-091-964
Anti-CD31 eBiosciences 11-0311-81
Anti-Ki-67 Thermo Scientific RM-9106-S
Anti-Cleaved Caspase-3 (Asp175)
Cell signalling #9579
Anti-CD274 (PD-L1, B7-H1) eBioscience 12-5982
Anti-CD279 (PD-1) eBioscience 11-9981
Anti-CD127 (IL-7Ra) eBioscience 17-1271
Anti- CD25 (IL-2Ra) eBioscience 12-0251
Anti-NK1.1 eBioscience 12-5941
Anti-CD3 eBioscience 11-0031
Supplementary Table 1
![Page 12: 50 MO P C MO P C , L C MV 40 re la tive V L 4 e xp re ssi o n › original › nature-assets › ...MOPC tumor bearing C57BL/6J mice were treated with 2x104 PFU LCMV peritumorally](https://reader033.fdocuments.in/reader033/viewer/2022060207/5f03fa9c7e708231d40bb751/html5/thumbnails/12.jpg)
Supplementary Table 2: List of murine Primers for Taqman qPCR List of commercially available TaqMan® Gene Expression Assays from Life technologies used for detection of murine gene expression via qPCR.
Primer number
Eukaryotic 18S RNA #4333760T
GAPDH Mm03302249_g1
Tipin Mm00600456_m1
Atp6ap2 Mm00510396_m1
Atp6v0b Mm01193846_g1
Pkmyt1 Mm01309244_m1
Arcn Mm00524375_m1
Copb1 Mm00446330_m1
Copa Mm00550231_m1
Mat2a Mm00728688_s1
Eif3g Mm00469383_m1
Eif3a Mm00468721_m1
Arhgap23 Mm01722379_m1
MYBL2 Mm00485340_m1
Ifnar1 Mm00439544_m1
Ifnar2 Mm00494916_m1
TGFß Mm01178820_m1
MMP14 Mm00485054_m1
MMP2 Mm00439498_m1
MMP9 Mm00442991_m1
PDGFß Mm00440677_m1
VEGFA Mm00437306_m1
VEGFB Mm00442102_m1
VEGFC Mm00437310_m1
VEGFD (Figf) Mm01131929_m1
FGFR1 Mm00438930_m1
FGFR2 Mm01269930_m1
FGFR3 Mm00433294_m1
EGF Mm00438696_m1
ANGPT1 Mm00456503_m1
SELL Mm00441291_m1
CCL5 Mm01302427_m1
CXCL3 Mm01701838_m1
Csf3 Mm00438334_m1
CXCL15 Mm00441263_m1
CXCL1 Mm04207460_m1
Supplementary Table 2
![Page 13: 50 MO P C MO P C , L C MV 40 re la tive V L 4 e xp re ssi o n › original › nature-assets › ...MOPC tumor bearing C57BL/6J mice were treated with 2x104 PFU LCMV peritumorally](https://reader033.fdocuments.in/reader033/viewer/2022060207/5f03fa9c7e708231d40bb751/html5/thumbnails/13.jpg)
Supplementary Table 3: List of murine Primers for SYBR Green-based qPCR List of commercially available QuantiTect Primer Assays used for detection of murine gene expression via qPCR.
Primer number
Gapdh QT01658692
IFN4 QT01774353
IFNß QT00249662
IRF7 QT00245266
OAS1 QT01056048
ISG15 QT02274335
Ly6C QT00247604
CCR2 QT02276813
CCL2 QT00167832
Supplementary Table 3
![Page 14: 50 MO P C MO P C , L C MV 40 re la tive V L 4 e xp re ssi o n › original › nature-assets › ...MOPC tumor bearing C57BL/6J mice were treated with 2x104 PFU LCMV peritumorally](https://reader033.fdocuments.in/reader033/viewer/2022060207/5f03fa9c7e708231d40bb751/html5/thumbnails/14.jpg)
Supplementary Table 4: List of human Primers for Taqman qPCR List of commercially available TaqMan® Gene Expression Assays from Life technologies used for detection of human gene expression via qPCR.
Supplementary Table 5: LCMV-NP Primer Sequences
Primer number
Eukaryotic 18S RNA #4333760T
IFNAR1 Hs01066116_m1
IFNAR2 Hs01022059_m1
CCR2 Hs00704702_s1
ITGAM Hs00167304_m1
SELP Hs00927900_m1
CXCL9 Hs00171065_m1
MMP9 Hs00957562_m1
CD14 Hs02621496_s1
CD16 Hs04334165_m1
IRF7 Hs01014809_g1
IFNB1 Hs01077958_s1
OAS1 Hs00973635_m1
USP18 Hs00276441_m1
PRKRA Hs00269379_m1
Primer Sequence
LCMV WE NP Forward 5’- CAA AGT ATT CAC ACG GCA TGG A
LCMV WE NP Reverse 5’- TGG GAG AGC ACC TAT AAC TGA TGA
Supplementary Table 4
Supplementary Table 5